Dr. Reddy’s Laboratories received a USFDA Form 483 with two observations after a pre-approval inspection of its FTO-11 plant.

The US regulator completed the inspection at the facility in Srikakulam, Andhra Pradesh, and handed over the form.

Source places the site at Pydibhimavaram, which is in the same area. The company told exchanges it plans to address the findings within the timeframe the regulator has set.

A Form 483 is a note an inspector issues at the end of a visit when they spot something that may break the rules.

It is not a final ruling that the plant has failed. Companies get a chance to reply with fixes. This was a pre-approval inspection.

That means the USFDA visited to judge whether the plant is fit to make a product that is waiting for approval. The count is small, only two observations.

Sources reports that the same plant received seven observations when it was inspected in July 2025.

Before using that statistic, compare it to the company’s previous filing because it comes from a single AI-assisted source. The drugmaker has had other inspections this quarter too.

Its Bachupally plant in Hyderabad was inspected from 6 to 14 August and received a Form 483 with four observations.

Dr.Reddy’s API facility in Jiutepec, Mexico, received a Form FDA 2953 with two observations after a records assessment that ran from 17 July to 8 September.

The company also made two partnership announcements in September. On 18 September, it agreed to distribute the dengue vaccine Qdenga in India’s private market with Takeda.

On 17 September, it widened its tie-up with Gilead Sciences on once-yearly lenacapavir for HIV prevention.

The filing and the report came out on the afternoon of 8 October. Neither gives a deadline for the company’s reply, and neither says which products depend on this plant.

Tired of guessing stocks to trade in daily? Tradz by EquityPandit empowers you with powerful tools like daily stock scans for Intraday, Swing & Investing, Market Predictions and much more. Download the Tradz by EquityPandit app today and take control of your investments!